$1.8M in CY2024 Part D spend65 claims · — beneficiaries · 329 plans surveyed
Questions a plan sponsor actually asks.
What is Epcoritamab-Bysp used for?
Epcoritamab-Bysp is a Bispecific CD20-directed CD3 T Cell Engager medication tracked in Medicare Part D.
Is there a generic for Epcoritamab-Bysp?
No. Epcoritamab-Bysp is brand-only with no generic equivalents currently in market.
How much does my plan pay for Epcoritamab-Bysp?
NADAC pricing data not currently available for this drug.
Is Epcoritamab-Bysp on the FDA shortage list?
No. Epcoritamab-Bysp is not currently on the FDA Drug Shortage Database.
6 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.
Same class. Different math.
Sources · every number above traces back.
Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book · NADAC unit costs: CMS NADAC weekly file · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.